BrightSpring Health price target raised to $41 from $37 at TD Cowen

TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $41 from $37 and keeps a Buy rating on the shares. The firm said the expected benefit from LDDs and generic conversions driving 2H adj. EBITDA growth are durable and are likely to benefit 2026 growth but it remains to be seen how 2H ultimately tracks.